Biogen Idec Inc. announced on October 9th that it was discontinuing development of its investigational rheumatoid arthritis (RA) drug baminercept after if failed to meet Phase II study [...]
|
|||||||
 |
Earlier this year British researchers raised a concern that anti-TNF drugs, as a result of their action in depressing the immune system, may increase the overall risk of cancer. Spanish researchers who are presenting their research at the American College of Rheumatology’s annual meeting in San Francisco say their studies do not support that [...] Fascinating news today about an 81 year-old retired physician with Alzheimer’s disease who received an injection of etanercept, under the brand name of Enbrel, a medication that is used to treat rheumatoid arthritis (RA). Prior to the injection the patient was in relatively good health but he was agitated and could not remember what state he [...] Several studies have been conducted into to effectiveness of the newest class of drugs, tumor necrosis factor (TNF)-alpha blockers, in treating rheumatoid arthritis. But there have been no published studies comparing TNF-alpha blockers with the older class of drugs, known as disease-modifying anti-rheumatic drugs (DMARDS), such as Remicade (infliximab), Enbrel (etanercept), and Humira (adalimumab). Recently a [...] The first international guidelines for the treatment of psoriatic arthritis has been developed and published by a group of rheumatologists, dermatologists, and patient [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments